AJOONI BIOTECH LTD Overview
| Field | Detail | Source |
|---|---|---|
| Legal name | Ajooni Biotech Limited | Annual Report FY2025-26 |
| Former name | Ajooni Biotech Private Limited (17 Feb 2010 – 27 Sep 2017) | Rights issue Letter of Offer 2024; ICICI Direct profile |
| Founding / incorporation date | 17 February 2010, at Chandigarh | Letter of Offer 2024 |
| Conversion to public company | 27 September 2017 (fresh certificate of incorporation, RoC Chandigarh) | Letter of Offer 2024 |
| Incorporation jurisdiction | India; Registrar of Companies, Chandigarh (Punjab) | Letter of Offer 2024 |
| Corporate Identification Number | L85190PB2010PLC040162 | Annual Report FY2025-26 |
| Registered office | D-118, Industrial Area, Phase VII, Mohali, Punjab 160055 (the AGM notice also uses PIN 160059) | Annual Report FY2025-26 |
| Corporate office | House No. 1769, Phase 3B2, Mohali, Punjab 160055 | Annual Report FY2025-26 |
| Manufacturing works | Gaib Di Pulli, Village Bullepur, Tehsil Khanna, District Ludhiana, Punjab 141401 (G.T. Road, Khanna) | Annual Report FY2025-26 |
| Stock exchange and ticker (current) | National Stock Exchange of India, Main Board — symbol AJOONI | NSE filings 2026 |
| Stock exchange and ticker (historical) | NSE Emerge (SME), listed 2 Jan 2018 — migrated May 2022 | Letter of Offer 2024; press release Dec 2022 |
| BSE | Several data vendors display BSE code 535040, but the company states its shares are listed only on NSE, and Upstox reports it as not listed on BSE | Directors' Report FY26 (Listing Fees section); Upstox |
| ISIN | INE820Y01021 (current, after the October 2022 split); INE820Y01013 (pre-split) | Directors' Report FY26; investor presentation June 2022 |
| CUSIP | Not applicable (no US listing) | — |
| Fiscal year end | 31 March | Annual Report FY2025-26 |
| Employees | 134 (latest, per Morningstar). A 3-year headcount trend is not publicly disclosed in the documents reviewed. Employee benefit expense rose from INR 1.80 Cr (FY24) to 2.76 Cr (FY25) and 4.57 Cr (FY26), which indicates a material workforce expansion linked to the new plant and the B2C dealer push | Morningstar; CMOTS; Annual Report FY26 |
| Statutory auditor | M/s Narinder Kumar and Company, Chartered Accountants, Mohali (FRN 0030737N; Peer Review Certificate 016014; engagement partner Narinder Kumar Garg, M.No. 080287). Appointed at the 14th AGM (17 Sep 2024) for five years to the 19th AGM (2029) | Directors' Report FY26; Q1 FY27 Limited Review Report |
| Secretarial auditor | M/s SDK & Associates, Punjab (PRC 7065/2025), FY2025-26 to FY2029-30 | Directors' Report FY26 |
| Registrar and transfer agent | Cameo Corporate Services Ltd, Chennai | Annual Report FY2025-26 |
| Banker | HDFC Bank Limited, G.T. Road, Khanna | Annual Report FY2025-26 |
| Shares outstanding | 18,12,43,598 equity shares of INR 2 each, after the allotment of 90,00,000 shares on 12 Aug 2026; 17,22,43,598 as at 31 Mar 2026 | AGM Notice 2026; NSE allotment filing 12 Aug 2026 |
| Market capitalisation (latest verified) | About INR 65–70 Cr. Share price INR 3.79–3.90 between 28 Aug and 10 Sep 2026; Value Research showed INR 70 Cr on 1 Sep 2026. No quote for 19 Oct 2026 could be independently verified | Anand Rathi; Value Research; Torus Digital |
| Website | https://ajoonibiotech.com | Annual Report FY2025-26 |
The supplied identifiers (ticker "AJOONI-SM.NS", exchange "National Stock Exchange of India") refer to the company's original listing on the NSE Emerge SME platform. That listing is outdated. Ajooni Biotech listed on NSE Emerge on 2 January 2018 and migrated to the NSE Main Board in May 2022 (source: rights issue press coverage, December 2022). The equity now trades under the symbol AJOONI on the NSE Main Board, and the NSE's Q2 FY26 integrated filing classifies the company as "Main Board". The entity profiled is unchanged: Ajooni Biotech Limited, CIN L85190PB2010PLC040162, website ajoonibiotech.com, India, NSE: AJOONI.
Ajooni Biotech is a Punjab-based micro-cap manufacturer of compound cattle feed, feed chips, camel feed, oil cakes and mineral and feed supplements. It positions itself as India's first listed "PURE VEG." animal-nutrition company, meaning formulations free of animal-derived inputs. The company runs a hybrid model. Historically most revenue has come from B2B and contract manufacturing for institutional buyers such as IFFCO Kisan, Mother Dairy, Paras (VRS Foods), Saahaj Dairy, NDDB Dairy Services and Patanjali-branded supplements. Since May 2024 it has also built its own "Ajooni" brand through a dealer network in north India. In FY26 a new Khanna plant tripled capacity to 1.8 lakh MTPA, and revenue rose 59% to INR 182.4 Cr. Margins, however, remain thin: EBITDA excluding other income was about 3.4% and PAT 2.4%. Returns on equity are about 5%. Large customer orders, promoter-group related-party ties and repeated equity dilution define the investment case.
The company's own description (Annual Report FY2025-26, paraphrased)
The FY26 Annual Report describes Ajooni as one of India's leading providers of animal nutrition and animal healthcare solutions. Its stated purpose is to raise dairy-farm productivity and livestock performance with scientifically formulated products. The portfolio spans compound cattle feed, cattle feed chips, camel feed, cotton oil cake, mustard oil cake and a range of feed supplements covering the livestock life cycle.
The company says it works with universities, research institutions and independent scientists on product development. It cites certifications under ISO 9001:2015, ISO 14001 (stated as "ISO:14000:2015"), ISO 45001 (stated as "ISO:45000:2018") and the ZED Gold scheme, together with BIS registration for ISI-marked feed and supplements. It also reports integrated ERP, PLC-based automated production controls, and environmental features at the plant (solar power, rainwater harvesting, a sewage treatment plant). Finally, it highlights a team of veterinary doctors and a field marketing force that provide doorstep technical service to customers.
For segment reporting, the Q1 FY27 results describe the business as a single segment ("Manufacturing of cattle feed and supplements") under Ind AS 108.
Independent characterisation
Ajooni is best understood as a regional, low-margin feed converter with an emerging brand layer:
-
Contract and institutional manufacturing core (B2B). Ajooni makes feed to the specifications of large buyers, including cooperatives, agri-input marketers (IFFCO Kisan under an exclusive agreement from March 2020) and branded marketers (Patanjali Gramodhyog Nyas for Patanjali Samvriddhi, Garbhanjali and Batisa-Pro). These are high-volume, thin-margin relationships. Buyers have considerable pricing power because they can switch suppliers and dairy cooperatives cap feed prices to retain members (Mordor Intelligence notes this pressure on manufacturers' margins). The ₹47.52 Cr order from one existing customer in February 2026, about 26% of FY26 revenue (derived), shows how concentrated this channel is.
-
Own-brand B2C channel. Launched in May 2024 in three states, including Punjab and Rajasthan. The company reported more than 100 dealers and a target of more than 300 distribution points (press release, 15 May 2024). Products include Gold Pashu Aahar, Buff Plus, 3 Star, 4 Star, Calf Starter and Transition Plus feeds, plus Calvit, Batisa, Liv and Min supplements (Morningstar company profile). The brand channel should carry better margins but needs working capital for dealer credit and inventory.
-
Commodity trading and processing adjacencies. Cotton oil cake and mustard oil cake are by-products traded as feed ingredients. Their prices follow oilseed cycles.
-
Optionality projects of uncertain status. In May 2024 the company announced moringa cultivation at Derabassi, Punjab, aimed at nutraceutical, feed and biodiesel uses, with management projecting an additional ₹150–200 Cr of annual revenue. No subsequent filing reviewed quantifies progress, so this should be treated as unproven.
Revenue model mix. Ajooni earns essentially all its revenue from product sales. It has no service, subscription or licensing income. The split between contract/B2B and own-brand sales is not publicly disclosed. Other income was ₹2.42 Cr in FY26, or 1.3% of revenue (Directors' Report FY26). This is a material share of a profit base of only ₹5.74 Cr PBT.
Value-chain position. The company sits mid-stream. It buys grains, de-oiled cakes, brans, molasses, minerals and vitamins. It processes them by grinding, mixing and pelleting or chipping, then sells feed to cooperatives, agri-marketers, dealers and, to a small extent, export customers (Avon Animal Health orders; exports "to two countries" per a 2024 DSIJ report). It neither owns herds nor controls milk procurement, so it captures none of the downstream dairy margin.
Customer types: (i) dairy cooperatives and milk processors, including Mother Dairy, Paras Dairy/VRS Foods, Saahaj Dairy and an unnamed "leading dairy cooperative" that placed a ₹25 Cr repeat order in August 2025; (ii) agri-input marketers (IFFCO Kisan); (iii) branded marketers (Patanjali Gramodhyog Nyas); (iv) government and quasi-government dairy bodies (NDDB Dairy Services contract, 2024; Directorate of Dairy Development, Punjab, cited in presentations); (v) dealers and farmers under the Ajooni brand; and (vi) small export customers.
End-markets: dairy cattle and buffalo nutrition, which is the core, plus camel feed (a niche relevant to Rajasthan) and adjacent feed-ingredient trading.
Strategy
Stated strategy themes (Annual Report FY26, MD's message, paraphrased)
-
Capitalise on India's dairy growth. India is the world's largest milk producer and has the largest livestock population, and management says demand for quality feed is structural.
-
A "new phase of growth and transformation". Management describes a strategic roadmap covering manufacturing, sales and marketing, procurement and supply chain, built around the newly commissioned integrated plant.
-
Operational efficiency and resilience. The company acknowledges raw-material price volatility, supply-chain pressure and a "challenging industry landscape" in Q4 FY26, and commits to cost control and efficiency.
-
Quality and certification as a differentiator. BIS ISI marking, ISO and ZED Gold certifications, and the "PURE VEG." positioning.
-
Sustainability. Solar power, rainwater harvesting and a sewage treatment plant at the manufacturing facility.
Initiative register (last 24 months, Oct 2024 – Oct 2026)
| Initiative | Date announced | Description | Target / KPI | Status | Source |
|---|---|---|---|---|---|
| New 1,20,000 MTPA plant, Khanna | Ongoing; target Nov 2025 (Aug 2025 update) | Capacity expansion to 1,80,000 MTPA with modern automation | Lower unit cost, margin expansion | Commercial production by Feb 2026; Q1 FY27 margins compressed | DSIJ Aug 2025; Indian Pharma Post Feb 2026 |
| Convertible warrants (₹45 Cr) | 6 Jan 2025 | 5 Cr warrants at ₹9 to promoters and investors | Strengthen capital base | EGM approved on 3 Feb 2025; no allotment reflected in share capital to 31 Mar 2026; status unconfirmed | Press release 6 Jan 2025; Directors' Report FY26 |
| Authorised capital to ₹50 Cr | 6 Jan 2025 | Capital headroom | — | Completed | Press release 6 Jan 2025 |
| Merger of Healthy Biosciences Ltd into Ajooni | Feb 2026 (board discussion) | Amalgamation of the promoter entity | "Strategic expansion" | Exploratory; no scheme or valuation filed in the material reviewed | Indian Pharma Post; Aliceblue |
| Preferential issue to promoter (₹3.87 Cr) | 29 Jun 2026 | 90 lakh shares at ₹4.30 | Fund warehousing (₹3.67 Cr) and general purposes (₹0.20 Cr) | Allotted on 12 Aug 2026 | AGM Notice 2026; NSE filing |
| Raw-material warehousing | 29 Jun 2026 | About 50,000 sq ft, about 10,000 MT storage at Bullepur | Procurement efficiency; buy commodities in season | Within one year of Aug 2026 | AGM Notice 2026 |
| Authorised capital to ₹70 Cr | 29 Jun 2026 | Adds 10 Cr shares of headroom | "Increased fund requirements and future plans" | Approved at 29 Jul 2026 AGM | AGM Notice 2026 |
| Own-brand B2C expansion | May 2024 (continuing) | Dealer network expansion beyond 100 dealers | More than 300 distribution points | Progress not updated publicly | Press release 15 May 2024 |
| Moringa diversification | May 2024 | Cultivation for nutraceutical, feed and energy uses | ₹150–200 Cr incremental annual revenue | No disclosed progress | Press release 21 May 2024 |
| BIS-certified mineral mixture | Nov 2024 | Certified supplement line | Quality-led supplement growth | Completed | Press release 18 Nov 2024 |
Medium-term targets and guidance
-
The May 2024 B2C press release included "AJOONI's Projection for Next 3 Years" running to FY2026-27.
-
No formal revenue or margin guidance appears in the FY26 Annual Report. The MD's message is qualitative.
Cost programme with quantified targets: none disclosed.
Products & Services
All products sit in the single segment. Pricing is not publicly disclosed for any product. The catalogue below is assembled from the Annual Report FY26, investor presentations (2022, 2024), the Morningstar company profile and press releases.
Compound cattle feed (own brand "Ajooni")
| Product | Description and function | Target customer | Launch / status | Source |
|---|---|---|---|---|
| Gold Pashu Aahar | Premium compound cattle feed for milch animals | Dairy farmers via dealers | Marketed under own brand (B2C push from 2024) | Morningstar profile |
| Buff Plus | Compound feed formulated for buffaloes, which dominate Punjab and Haryana milk production | Buffalo dairy farmers | Current | Morningstar profile |
| 3 Star | Mid-tier compound cattle feed | Price-sensitive smallholders | Current | Morningstar profile |
| 4 Star | Higher-protein, higher-energy compound cattle feed | Higher-yield herds | Current | Morningstar profile |
| Calf Starter | Starter ration for calves to support rumen development | Calf rearers, dairy farms | Current | Morningstar profile |
| Dairy Calf Grower | Grower ration for heifers | Dairy farms | Listed in the 2022 own-product portfolio | Investor presentation June 2022 |
| Transition Plus | Transition-cow feed for the periparturient period | Commercial dairies | Current | Morningstar profile |
Feed formats and other feeds
| Product | Description | Target customer | Source |
|---|---|---|---|
| Compound Cattle Feed (pellet/mash) | Core volume product, ISI-marked under BIS | Cooperatives, agri-marketers, dealers | Annual Report FY26 |
| Cattle Feed Chips | Chipped feed format | Institutional buyers | Annual Report FY26 |
| Camel Feed | Niche formulation for camels | Rajasthan and arid-region buyers | Annual Report FY26 |
| Cotton Oil Cake | Protein-rich feed ingredient (by-product of cottonseed crushing) | Feed manufacturers, farmers | Annual Report FY26 |
| Mustard Oil Cake | Protein-rich feed ingredient (by-product of mustard crushing) | Feed manufacturers, farmers | Annual Report FY26 |
Feed supplements (own brand)
| Product | Description (inferred from naming and company materials) | Source |
|---|---|---|
| Calvit | Calcium and vitamin supplement | Morningstar profile |
| Batisa | Herbal/digestive supplement | Morningstar profile |
| Liv | Liver-support supplement | Morningstar profile |
| Min | Mineral mixture. The mineral mixture received BIS certification in November 2024 | Morningstar profile; press release 18 Nov 2024 |
Contract-manufactured and co-branded products
| Product | Brand owner / channel | Description | Source |
|---|---|---|---|
| Patanjali Samvriddhi | Patanjali Gramodhyog Nyas | Cattle feed supplement | Ventura; Zerodha profile; investor presentation May 2024 |
| Patanjali Garbhanjali | Patanjali Gramodhyog Nyas | Supplement for pregnant animals | Same |
| Patanjali Batisa-Pro | Patanjali Gramodhyog Nyas | Digestive/herbal supplement | Same |
| IFFCO-branded animal feed | IFFCO Kisan (exclusive agreement, March 2020) | ISI-marked "PURE VEG." cattle feed | Investor presentations 2022 and 2024 |
| Institutional cattle feed | Mother Dairy, Paras Dairy (VRS Foods), Saahaj Dairy, NDDB Dairy Services, unnamed cooperatives | Feed to buyer specification | Investor presentations; press releases 2024–2026 |
| Export feed supplements | Avon Animal Health (export and repeat orders) | Feed supplements | Reuters headlines via Zerodha (dates not specified) |
Development-stage initiatives
| Initiative | Description | Status | Source |
|---|---|---|---|
| Moringa cultivation | Nursery and plantation at Derabassi, Punjab, for leaves (nutraceutical and feed ingredient), seed oil (biodiesel and aviation-fuel feedstock) and bark (activated carbon). Management projected ₹150–200 Cr additional annual revenue | No progress or revenue disclosed after 2024 | Press release 21 May 2024; DSIJ |
Financial Narrative
Basis. FY2025 and FY2026 come from the Directors' Report FY26 and the audited results of 28 May 2026. FY2022–FY2024 P&L items come from CMOTS data (Arihant Capital), which matches company-reported FY25 PBT of ₹4.33 Cr. Balance-sheet items for FY22–FY25 come from IIFL and Bajaj Broking, and FY26 from the audited Statement of Assets & Liabilities. Cash-flow history comes from StockAnalysis and should be treated as vendor-derived. All figures are in INR Cr unless noted.
Per-share data
FY26 EPS of ₹0.25 is as reported (FY26 results). Earlier EPS figures are analyst-derived on year-end share counts and are not adjusted for the bonus element of the rights issues. The company's reported historical EPS may therefore differ. The Q1 FY27 results template labels EPS "Face Value of Rs.10/- each", which is a labelling error because face value has been ₹2 since October 2022.
Margins
Revenue CAGR. FY2022–FY2026 (4 years): 25.3%. FY2021–FY2026 (5 years, FY21 revenue ₹51.04 Cr per CMOTS): about 29.0%. Value Research reports a 5-year revenue growth score of 30.1%, consistent with this.
Commentary. Revenue followed a step-function pattern: a pandemic-era jump in FY22, flat sales in FY23–FY24, then rapid growth in FY25–FY26. The FY26 increase came from large institutional orders (₹25 Cr in August 2025, ₹4.8 Cr in September 2025, ₹47.52 Cr in February 2026) and new capacity reaching production in the second half. Quarterly revenue almost doubled from about ₹31 Cr in Q1/Q2 FY26 to ₹58.75 Cr in Q3 and ₹60.62 Cr in Q4.
Gross margin widened to 18.9%, but most of that gain was absorbed by "other expenses" (₹23.62 Cr, up from about ₹10 Cr) and by employee costs. As a result, EBITDA margin excluding other income improved only modestly to 3.4%. Other income has been between ₹2.07 Cr and ₹2.42 Cr in each of the last three years, equal to 42–73% of PBT. Core operating profitability is therefore materially weaker than headline PAT suggests. For example, FY24 PBT of ₹3.00 Cr included ₹2.19 Cr of other income.
Quarterly trajectory (INR lakh)
Sources: Q1 FY27 results (Q1FY26, Q4FY26, Q1FY27); Q2 FY26 integrated filing; Capital Market/Arihant for Q3 FY26 (sales ₹58.75 Cr, PBT ₹2.36 Cr, PAT ₹1.65 Cr, rounded).
Inflection in Q1 FY27. Revenue was ₹63.49 Cr (+103% YoY), but PAT fell 45% YoY to ₹43.18 lakh. Derived gross margin compressed to 14.7%, against 18.9% in Q4 FY26 and 18.1% in Q1 FY26. Finance costs rose almost six-fold YoY to ₹48.21 lakh, and depreciation more than tripled to ₹80.27 lakh because of the new plant. Derived EBITDA margin excluding other income was about 2.6%. The pattern is consistent with large low-margin institutional volumes being run through a higher fixed-cost base financed by short-term debt.
Balance sheet
Debt maturity split (INR Cr)
Sources: Directors' Report FY26 item 34 (₹1,776.29 lakh versus ₹193.96 lakh); audited and Q1 FY27 Statements of Assets & Liabilities.
Balance-sheet observations
Loans and other financial assets are large: At 31 March 2026 the company held ₹15.00 Cr of non-current "other financial assets" and ₹14.15 Cr of current "loans", about ₹29 Cr or 24% of total assets (audited Statement of Assets & Liabilities). The counterparties and terms were not identifiable in the material reviewed. During the same period the company drew ₹16.22 Cr of short-term borrowings. Lending or advancing funds while borrowing to finance working capital needs to be explained, especially given the promoter-group related parties.
Inventory build: Inventory rose to ₹39.46 Cr at FY26 and ₹41.81 Cr at 30 June 2026. That equals about 97 days of material consumption (derived), up from about 34 days in FY22.
Non-current investments: of ₹2.45 Cr produced an other-comprehensive-income loss of ₹1.21 Cr in FY26. Total comprehensive income was therefore ₹3.11 Cr, against PAT of ₹4.32 Cr.
Cash flow
Cash-flow figures come from StockAnalysis, converted from INR million. Sources conflict. Bajaj Broking shows different operating cash-flow values for the same years, for example −₹3.40 Cr and −₹5.13 Cr against StockAnalysis's ₹22.91 Cr and −₹5.58 Cr in the corresponding columns. The original filed cash-flow statements should be used for any investment decision. Equity raised is derived from share-capital changes multiplied by issue prices. The FY25 column reflects the June 2024 rights issue (FY2024-25).
Commentary. Cumulative FY22–FY26 free cash flow is about −₹31.6 Cr on these vendor figures. Cumulative PAT over the same period is ₹12.0 Cr, and roughly ₹65 Cr of equity was raised over the period. Growth has been funded almost entirely by shareholders and, since FY26, by short-term bank debt. Earnings have not converted into cash.
Ratios
All ratios are analyst-derived. Cash conversion cycle for FY26: about 111 days (97 days inventory + 36 days receivables − 22 days payables, with trade payables of ₹8.91 Cr). Payables are not available for earlier years, so the cycle is not computed for them.
Interpretation. Returns have stayed in a narrow 4–7% band for five years, well below India's cost of equity. Capital has been raised and deployed at returns that destroy value. Leverage rose in FY26 for the first time in three years, and on Q1 FY27 annualised EBITDA (about ₹7.8 Cr including other income) net debt of ₹26.5 Cr is roughly 3.4x (derived). Receivable days have improved sharply, which is consistent with cooperatives and institutional buyers paying faster. That improvement has been more than offset by inventory build-up.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue — cattle feed and supplements (INR Cr) | 80.11 | 114.69 | 182.38 |
Segment PBT (INR Cr) | 3.00 | 4.33 | 5.74 |
Segment PBT margin (%) | 3.74 | 3.78 | 3.15 |
YoY revenue growth (%) | 7.5 | 43.2 | 59.0 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 74.04 | 74.49 | 80.11 | 114.69 | 182.38 |
Revenue growth YoY (%) | 45.1 | 0.6 | 7.5 | 43.2 | 59.0 |
Other income (INR Cr) | 0.04 | 0.29 | 2.19 | 2.07 | 2.42 |
Gross profit — revenue minus materials (INR Cr, derived) | 10.03 | 8.75 | 9.76 | 17.67 | 34.46 |
EBITDA excluding other income (INR Cr, derived) | 3.07 | 2.77 | 2.24 | 3.69 | 6.26 |
EBITDA including other income (INR Cr) | 3.11 | 3.06 | 4.43 | 5.76 | 8.67 |
Depreciation and amortisation (INR Cr) | 1.11 | 1.00 | 0.87 | 1.09 | 2.21 |
Operating income / EBIT incl. other income (INR Cr) | 2.00 | 2.06 | 3.56 | 4.66 | 6.47 |
Finance costs (INR Cr) | 0.54 | 0.48 | 0.56 | 0.33 | 0.73 |
Pre-tax income (INR Cr) | 1.46 | 1.58 | 3.00 | 4.33 | 5.74 |
Tax (INR Cr) | 0.41 | 0.45 | 0.84 | 0.96 | 1.42 |
Net income (INR Cr) | 1.05 | 1.13 | 2.16 | 3.37 | 4.32 |
Employee benefit expense (INR Cr) | 1.48 | 1.76 | 1.80 | 2.76 | 4.57 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS basic (INR, FV 2; FY22–FY25 derived on year-end shares) | 0.21 | 0.13 | 0.25 | 0.20 | 0.25 |
EPS diluted (INR) | 0.21 | 0.13 | 0.25 | 0.20 | 0.25 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Year-end shares outstanding (Cr) | 5.00 | 8.76 | 8.76 | 17.22 | 17.22 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 13.5 | 11.7 | 12.2 | 15.4 | 18.9 |
EBITDA margin excl. other income (%) | 4.15 | 3.72 | 2.80 | 3.22 | 3.43 |
Operating (EBIT) margin (%) | 2.70 | 2.77 | 4.44 | 4.06 | 3.55 |
Pre-tax margin (%) | 1.97 | 2.12 | 3.74 | 3.78 | 3.15 |
Net margin (%) | 1.42 | 1.52 | 2.70 | 2.94 | 2.37 |
Income Statement
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Lakh) | 3,126.77 | 3,173.51 | 5,875 | 6,062.21 | 6,349.07 |
Profit before tax (INR Lakh) | 102.72 | 123.37 | 236 | 112.03 | 65.44 |
Net profit (INR Lakh) | 78.14 | 93.21 | 165 | 94.72 | 43.18 |
Finance costs (INR Lakh) | 8.46 | 0 | 0 | 28.95 | 48.21 |
Depreciation (INR Lakh) | 24.83 | 0 | 0 | 89.79 | 80.27 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 29.02 | 58.73 | 47.52 | 95.05 | 120.37 |
Cash and equivalents (INR Cr) | 0.06 | 0.31 | 0.43 | 6.83 | 0.42 |
Total debt (INR Cr) | 5.35 | 5.18 | 2.17 | 1.94 | 17.76 |
Net debt (INR Cr) | 5.29 | 4.87 | 1.74 | -4.89 | 17.34 |
Shareholders' equity (INR Cr) | 16.39 | 41.67 | 42.71 | 88.08 | 91.19 |
Goodwill and intangibles (INR Cr) | 0 | 0 | 0 | 0.48 | 0.36 |
Inventories (INR Cr) | 5.88 | 6.99 | 15.37 | 23.99 | 39.46 |
Trade receivables (INR Cr) | 13.84 | 20.55 | 12.96 | 16.22 | 17.83 |
Net working capital (INR Cr) | 11.87 | 19.46 | 29.32 | 57.18 | 47.13 |
Financial Analysis
| Item | 31 Mar 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|
Long-term borrowings | 1.94 | 1.54 | 1.41 |
Short-term borrowings | 0.00 | 16.22 | 25.50 |
Total borrowings | 1.94 | 17.76 | 26.91 |
Cash and equivalents | 6.83 | 0.42 | 0.37 |
Net debt | -4.89 | 17.34 | 26.54 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 3.68 | -5.58 | 22.91 | -17.74 | -5.73 |
Capital expenditure (INR Cr) | 2.12 | 1.36 | 5.60 | 2.03 | 18.03 |
Free cash flow (INR Cr) | 1.56 | -6.94 | 17.31 | -19.77 | -23.76 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Equity raised (INR Cr, derived) | 0 | 22.5 | 0 | 42.3 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 6.6 | 3.9 | 5.1 | 5.2 | 4.8 |
ROA on average assets (%) | 3.7 | 2.6 | 4.1 | 4.7 | 4.0 |
ROIC, post-tax EBIT / (equity + debt − cash) (%) | 6.6 | 3.1 | 5.8 | 4.3 | 4.5 |
Current ratio (x) | 2.18 | 2.28 | 10.74 | 12.86 | 2.72 |
Debt-to-equity (x) | 0.33 | 0.12 | 0.05 | 0.02 | 0.19 |
Net debt / EBITDA incl. other income (x) | 1.70 | 1.59 | 0.39 | -0.85 | 2.00 |
Interest coverage, EBIT / finance cost (x) | 3.7 | 4.3 | 6.4 | 13.9 | 8.9 |
Asset turnover (x) | 2.60 | 1.70 | 1.51 | 1.61 | 1.69 |
Inventory days on material cost | 33.6 | 38.6 | 80.3 | 90.1 | 97.3 |
Receivable days on revenue | 68.2 | 100.7 | 59.0 | 51.6 | 35.7 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India — all channels (INR Cr) | 80.11 | 114.69 | 182.38 |
India growth YoY (%) | 7.5 | 43.2 | 59.0 |
Region Overview
| Region | Evidence | Assessment |
|---|---|---|
Punjab (home market) | Plant at Khanna; Directorate of Dairy Development, Punjab, cited as an institutional link; own-brand launch state | Core volume base; freight advantage within roughly 300 km |
Rajasthan | Own-brand launch state; camel-feed niche | Growth market for brand and niche feeds |
Third own-brand state | Not named in the material retrieved (press release 15 May 2024 lists three states) | — |
National institutional buyers | IFFCO Kisan, Mother Dairy (Delhi NCR), Paras/VRS Foods (UP/NCR), Saahaj (UP), NDDB Dairy Services | Pan-north-India institutional demand |
Exports | Avon Animal Health orders | De minimis |
“—” = not publicly disclosed.
Share Price & Returns
| Window | Return (%) | Reference point | Source |
|---|---|---|---|
3 months (to 6 Aug 2026) | -8.76 | — | Ventura |
6 months (to 28 Aug 2026) | -17.79 | — | Anand Rathi |
1 year (to 28 Aug 2026) | -29.68 | — | Anand Rathi |
3 years (to 28 Aug 2026) | 6.16 | Value Research shows 3.4% to 21 Jul 2026 | Anand Rathi; Value Research |
5 years (to 6 Aug 2026) | -54.88 (CAGR -14.72) | — | Ventura |
52-week range | ₹3.40 (8 Jun 2026) to ₹5.94 | — | Ventura; Value Research |
All-time high | ₹12.72 (9 Feb 2022) | — | Ventura |
Latest verified price | ₹3.90 (10 Sep 2026); ₹3.79 (28 Aug 2026) | — | Torus; Anand Rathi |
Monthly close Mar 2025 | ₹5.60 (market cap ₹96.46 Cr) | — | Arihant Capital |
Valuation Multiples
| Multiple | Ajooni | Peer reference | Source / basis |
|---|---|---|---|
Market cap | About ₹70 Cr | — | 18.12 Cr shares × about ₹3.85 |
P/E (TTM, Q2 FY26 – Q1 FY27 PAT ₹3.96 Cr) | About 17.6x | Peer median 30.68x (Value Research, Jul 2026); Godrej Agrovet 34.7x | Derived; Value Research; Tickertape |
P/B (book about ₹95.5 Cr post-allotment) | About 0.73x | Peer median 1.68x (Value Research); KSE 3.07x; Godrej Agrovet 3.81x | Derived |
EV (market cap + ₹26.91 Cr debt − ₹0.37 Cr cash) | About ₹96.5 Cr | — | Derived |
EV/EBITDA (FY26 EBITDA incl. other income ₹8.67 Cr) | About 11.1x | — | Derived |
EV/Sales (TTM revenue ₹214.6 Cr) | About 0.45x | — | Derived |
Dividend yield | 0% | — | No dividends ever paid |
Bucket Details
| Bucket | INR Cr |
|---|---|
Short-term borrowings (≤ 12 months, working capital) | 25.50 |
Long-term borrowings (> 12 months) | 1.41 |
Total | 26.91 |
Capital Markets
| Item | Value |
|---|---|
Authorised capital | ₹70 Cr (35 Cr shares of ₹2), approved 29 Jul 2026 |
Paid-up capital | ₹36.25 Cr (18,12,43,598 shares), derived after the Aug 2026 allotment |
Outstanding warrants | Status of the Jan 2025 programme is unconfirmed; no conversions reflected in paid-up capital |
Analyst Conclusions
Management guidance
No quantitative guidance is in force. Management's FY26 commentary describes a "new phase of growth and transformation" built on the new plant and a roadmap across manufacturing, sales, procurement and supply chain (MD's message, Annual Report FY26).
Consensus expectations
None available.
Run-rate reference (derived). Q1 FY27 revenue annualises to about ₹254 Cr and Q1 FY27 PAT to about ₹1.7 Cr. That profit run-rate is well below FY26 PAT of ₹4.32 Cr, unless margins recover or other income normalises upward.
Bull case
-
Operating leverage on new capacity. Revenue doubled YoY in Q1 FY27. If gross margin returns to the FY26 level of about 19% from 14.7%, while depreciation and employee costs are now largely fixed, EBITDA could expand disproportionately. In Q3 FY26 the company achieved a 5.16% OPM.
-
Deep value on book. At about 0.73x P/B and about 0.45x EV/Sales, the market already prices in sub-par returns. Small improvements in ROE from about 5% could drive re-rating, especially with promoter buying at ₹4.30 in August 2026.
-
Institutional demand validation. Repeat large orders (₹25 Cr, ₹47.52 Cr) from top cooperatives and NDDB Dairy Services, plus IFFCO exclusivity, provide volume visibility in a market growing at about 6.4% annually.
Bear case
-
Value-destructive growth. Five years of ROE between 3.9% and 6.6%, cumulative negative FCF of about ₹32 Cr, and about ₹65 Cr of equity raised since FY22 against ₹12 Cr of cumulative PAT show that growth has not created shareholder value. Q1 FY27 PAT fell 45% YoY despite revenue doubling.
-
Balance-sheet quality and leverage. About ₹29 Cr sits in loans and other financial assets of undisclosed nature while short-term debt has risen to ₹25.50 Cr. Cash is ₹0.37 Cr, and finance costs are rising steeply.
-
Governance and dilution overhang. The promoter holds 30.5%. Combined Chairman/MD/CFO roles, independent directors shared with the promoter entity, a pending related-party merger, and authorised capital raised to 35 Cr shares all point to further dilution and minority-shareholder risk.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q2 FY27 results | By mid-November 2026 | Gross margin recovery above 17%; finance cost trend; inventory and debt levels |
| Q3 FY27 results | Late January / February 2027 | Execution and margin of the ₹47.52 Cr-type orders |
| Healthy Biosciences merger | Any time | Scheme filing, swap ratio, independent valuation, NSE and NCLT process |
| Disclosure on loans and advances | FY27 annual report / AGM | Counterparties and related-party nature of ₹29 Cr in financial assets |
| Further equity issuance | Any time (headroom created) | Pricing, allottees, related-party involvement |
| Warehouse capex completion | By about August 2027 | Procurement savings |
| New large orders | Ongoing | Customer diversification versus concentration |
| Status of January 2025 warrants | Any time | Formal lapse or conversion disclosure |
| Commodity prices (maize, cottonseed and mustard cake) | Continuous | Gross-margin sensitivity |
Analyst verdict
Ajooni Biotech has turned itself, in volume terms, from a ₹74 Cr regional feed miller into a ₹180–250 Cr run-rate business with three times its former capacity. On revenue, the past two years mark a genuine inflection. The new Khanna plant, credentials with IFFCO Kisan, Mother Dairy, NDDB Dairy Services and Patanjali, and repeated cooperative orders show that the company can win and execute large institutional volumes in a structurally growing market.
Value creation, however, is about returns on capital, and the record there is poor. Return on equity has stayed between 4% and 7% for five years. Free cash flow has been persistently negative. Each phase of growth has been paid for with new equity: the share count has risen 3.6x since FY22, and authorised capital has just been raised again. Headline profit depends on other income, and the core business earns an EBITDA margin of about 3%. The first quarter on the new asset base (Q1 FY27) showed the risk plainly: revenue doubled while net profit nearly halved, because commodity costs, depreciation and interest all hit together.
Governance needs the most scrutiny. The founder is Chairman, MD and CFO. Two independent directors also sit on the board of the promoter entity, which has just been allotted shares and is a candidate for amalgamation. About ₹29 Cr of loans and financial assets sit on the balance sheet without clear disclosure while the company borrows short-term.
The stock's discount to book (about 0.7x) is therefore justified rather than an anomaly. An investment case requires evidence on three fronts: (1) gross margins returning to about 19% at scale, so that EBITDA margins move toward 5%; (2) transparent disclosure of the loan book and arm's-length terms for any Healthy Biosciences merger; and (3) a pause in dilution. Until then, Ajooni is a high-risk, governance-sensitive micro-cap suited to monitoring rather than accumulation. The Q2 and Q3 FY27 results are the key tests.
Appendix A — Data reconciliation notes
-
Revenue definitions. StockAnalysis reports FY26 revenue of ₹184.8 Cr including other operating revenue, and Value Research reports ₹182 Cr TTM.
-
FY25 revenue. Torus reports ₹116.76 Cr (likely total income) against company revenue from operations of ₹114.69 Cr. The company figure is used.
-
Cash-flow history. StockAnalysis and Bajaj Broking conflict materially. Neither has been verified against the filed cash-flow statements.
-
Ventura's Q4 FY26 revenue figure of "₹587.53 Cr" is a vendor data error. The actual figure is ₹60.62 Cr (₹6,062.21 lakh).
-
FY25 PBIT is printed as ₹4,33,35,012 in the FY26 Directors' Report. Arithmetic (PBDIT ₹575.70 lakh minus depreciation ₹109.35 lakh) gives ₹466.35 lakh, so the printed figure appears to be a typographical error.
-
Accounting framework. The Directors' Report cites "Accounting Standards 21" in one place and Ind AS elsewhere. The results are stated to be prepared under Ind AS.
-
Screener's description of Ajooni as active in "aquaculture" is not supported by any company filing reviewed.
-
BSE listing. Vendors show BSE code 535040, but the company states NSE as its only listing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Designation | DIN | Tenure / appointment | Background | Age | FY26 remuneration (INR Lakh) |
|---|---|---|---|---|---|---|
Jasjot Singh | Chairman, Managing Director and CFO (promoter) | 01,937,631 | Director since 4 Sep 2017 (per MarketScreener); re-designated MD w.e.f. 1 Apr 2025 | Founder. | — | 52.00 (salary and perquisites) |
Gursimran Singh | Whole-Time Director (CEO for about 8 years) | 02,209,675 | Board since 13 Aug 2020; WTD w.e.f. 14 Aug 2025; reappointed on rotation at the 2026 AGM | B.Com, MBA; more than 15 years in animal husbandry and crop/supplement cultivation; director of Healthy Biosciences Ltd; holds 1,915 Ajooni shares | 38 (born 23 Feb 1988) | 12.65 |
Partek Singh | Executive Director | 07,864,006 | Not publicly disclosed (DIN series suggests about 2017) | — | — | Nil |
Simmi Chhabra | Independent Director (woman); chairs Audit, NRC and SRC | 07,870,398 | — | Not publicly disclosed; holds 100 shares | — | 0.49 (sitting fees) |
Ramandeep Singh | Independent Director | 07,896,086 | — | Also an Independent Director of Healthy Biosciences Ltd (the promoter entity); holds 20,400 shares | — | 0.49 |
Imteshwar Singh (Bhatia) | Independent Director | 07,864,007 | — | — | — | 0.49 |
Ishtneet Bhatia | Independent Director | 10,440,990 | Not publicly disclosed (DIN issued about 2024) | Also an Independent Director of Healthy Biosciences Ltd | — | 0.29 |
Total | — | — | — | — | — | 66.41 |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Notes |
|---|---|---|
Jasjot Singh | MD and CFO | The CFO role is combined with the MD role |
Swati Vijan | Company Secretary and Compliance Officer (FCS 13627) | Remuneration not publicly disclosed in the material reviewed |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Apr 2025 | Jasjot Singh re-designated Managing Director | Formalises founder's executive role |
14 Aug 2025 | Gursimran Singh re-designated Whole-Time Director | Elevates long-serving CEO to the Board in an executive capacity |
29 Jul 2026 | Gursimran Singh reappointed on retirement by rotation | Routine |
FY26 | No director resignations | Corporate Governance Report FY26 |
Shareholding Pattern
| Category | Shares (pre-allotment, Jun 2026) | % | Shares (post-allotment, Aug 2026) | % |
|---|---|---|---|---|
Promoter — individuals | 4,63,24,766 | 26.89 | 4,63,24,766 | 25.56 |
Promoter — Healthy Biosciences Ltd | 0 | 0.00 | 90,00,000 | 4.97 |
Total promoter group | 4,63,24,766 | 26.89 | 5,53,24,766 | 30.53 |
Public — resident individuals | 11,28,52,316 | 65.52 | 11,28,52,316 | 62.27 |
Public — NRIs | 54,48,663 | 3.16 | 54,48,663 | 3.01 |
Public — bodies corporate | 37,72,705 | 2.19 | 37,72,705 | 2.08 |
Public — HUF, LLP and others | 38,45,148 | 2.23 | 38,45,148 | 2.12 |
Institutions (FII, DII, MF, banks) | 0 | 0.00 | 0 | 0.00 |
Total | 17,22,43,598 | 100 | 18,12,43,598 | 100 |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with Ajooni | Scale indicator | Relative positioning |
|---|---|---|---|---|
Godrej Agrovet Ltd | Listed diversified agri-business | Cattle, poultry and aqua feed nationally; north-India cattle feed | Consolidated FY26 revenue above ₹10,000 Cr; Animal Feed segment ₹3,672 Cr in 9M FY26; cattle feed volumes +18–24% in FY26 | National leader in branded compound feed, with scale and R&D far beyond Ajooni |
KSE Ltd | Listed cattle feed and dairy (Kerala) | Pure-play compound cattle feed | FY26 revenue ₹1,680 Cr; PAT ₹84.04 Cr; Q1 FY27 PAT ₹0.94 Cr | Closest listed pure-play peer; dominant in Kerala, not in north India |
Amul / GCMMF and member unions | Cooperative | Cattle feed plants serving member farmers | Not disclosed separately | Price-setter in Gujarat; cooperatives cap feed prices |
Punjab State Cooperative Milk Producers' Federation (Milkfed, "Verka") | State cooperative | Cattle feed in Punjab, Ajooni's home market | — | Direct regional competitor with captive milk-procurement access |
Cargill India (Purina) | Multinational (unlisted in India) | Compound and specialty feeds | — | Premium technology-led player |
Anmol Feeds | Private | Poultry, cattle and fish feed (east and north India) | — | Larger regional private feed miller |
Kapila Krishi Udyog (Kapila Pashu Aahar) | Private | Cattle feed (Maharashtra and national) | — | Established cattle feed brand |
SKM Animal Feeds & Foods | Private | Cattle and poultry feed (south India) | — | Regional private |
Mayank Cattle Food Ltd | Listed (SME) | Cattle feed (Gujarat) | — | Small listed peer of similar scale |
Avanti Feeds Ltd | Listed | Aqua feed (adjacent category; Ajooni has no aqua product despite Screener's "aquaculture" label) | — | Adjacent, not a direct competitor |
Venky's (India) Ltd | Listed | Poultry feed (adjacent) | — | Adjacent |
Unorganised local feed mixers and farm-mixed rations | Informal | Price-led competition for smallholders | Not measurable | The largest de facto competitor in rural Punjab |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Ajooni Biotech (FY26) | KSE Ltd (FY26) | Godrej Agrovet (FY26) | Godrej Agrovet — Animal Feed segment |
|---|---|---|---|---|
Revenue (INR Cr) | 182.4 | 1,680 | — | 3,672 (9M FY26) |
Revenue growth YoY (%) | 59.0 | 1.9 | — | 1.0 (9M FY26 YoY) |
Net profit (INR Cr) | 4.32 | 84.04 | — | — |
Net margin (%) | 2.4 | 5.0 (derived) | — | — |
P/E (x) | About 17–18 (TTM, Sep 2026, derived) | Negative/not meaningful on TTM (Tickertape) | 34.7 (Tickertape) | — |
P/B (x) | About 0.7 | 3.07 (Tickertape) | 3.81 (Tickertape) | — |



